Submissions received during the consultation on the Guideline Monitoring and Evaluation Plan
- AbbVie Corporation (PDF 226 KB)
- Amgen Canada Inc. (PDF 393 KB)
- Arthritis Society (PDF 139 KB)
- Astellas Pharma Canada Inc. (PDF 638 KB)
- Bayer Inc. (PDF 206 KB)
- Best Medicines Coalition (PDF 243 KB)
- Biogen Canada (PDF 167 KB)
- BIOQuébec [in French only] (PDF 203 KB)
- BIOTECanada (PDF 151 KB)
- Boehringer Ingelheim (Canada) Ltd (PDF 192 KB)
- Canadian Health Research Forum (PDF 449 KB)
- Canadian Life and Health Insurance Association (CLHIA) (PDF 624 KB)
- Canadian Organization for Rare Disorders (CORD) (PDF 141 KB)
- Council of Senior Citizens' Organization of BC (PDF 169 KB)
- Cystic Fibrosis Canada (PDF 260 KB)
- Elvium Life Sciences (PDF 111 KB)
- Gastrointestinal Society (PDF 197 KB)
- Innovative Medicines Canada (PDF 135 KB)
- Janssen Inc (PDF 134 KB)
- Life Sciences BC (PDF 217 KB)
- Life Sciences Ontario (PDF 202 KB)
- McKesson Canada Corporation (PDF 548 KB)
- Medicines Access Coalition BC (PDF 839 KB)
- Merck Canada Inc. (PDF 178 KB)
- Multiple Sclerosis Society of Canada (PDF 245 KB)
- Novartis Pharma Canada Inc (PDF 423 KB)
- Pfizer Canada ULC (PDF 115 KB)
- Protect our Access (umbrella group for 15 patient groups) (PDF 155 KB)
- Sanofi Canada (PDF 139 KB)
- Save Your Skin Foundation (PDF 483 KB)
- Servier Canada Inc. (PDF 196 KB)
- Sunovion Pharmaceuticals Canada Inc. (PDF 192 KB)
- Takeda Canada (PDF 145 KB)
- The Canadian Association for Pharmacy Distribution Management (CAPDM) (PDF 242 KB)
- The Canadian Forum for Rare Innovators (RAREi) (PDF 218 KB)
- The Neighbourhood Pharmacy Association of Canada (PDF 160 KB)
- Vaccine Industry Committee (PDF 96 KB)
Page details
- Date modified: